Novel target is fifth in a series of potential targets on prion-like strains of misfolded Amyloid beta, implicated in the development and progression of AD
TORONTO, June 21, 2016 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative
"Multiple therapeutic candidates against all five of the novel targets we have identified demonstrated, during the screening phase, selective binding to misfolded strains of Amyloid beta, with no measurable off-target binding," said Dr. Elliot Goldstein, ProMIS CEO. "These candidates are currently being evaluated for their binding profiles in cadaveric brain tissue from patients with a confirmed diagnosis of Alzheimer's. We are looking forward to the results of these validation studies, which will enable the selection of therapeutic products for drug development."
ProMIS Neurosciences submitted a provisional patent application for its fifth novel Alzheimer's disease target to the United States Patent Office on June 20, 2016, pursuant to its expanded license agreement with the University of British Columbia (announced on October 8, 2015).
The Company applied its unique, proprietary discovery platforms, ProMISTM and Collective Coordinates, to identify this fifth, novel target (epitope) on prion-like strains of misfolded Ab.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at:www.promisneurosciences.com
Follow us on TwitterLike us on LinkedIn
SOURCE ProMIS Neurosciences Inc.
Subscribe to our Free Newsletters!